In brief

A meta-analysis of randomized trials found no difference in WOMAC or Oxford Knee Score at the studied time points despite differences in technical accuracy.
Short early series may show recovery differences but cannot answer the long-term benefit question.
Revision and survivorship evidence remains constrained by follow-up, mixed device generations, and uncommon events.
Use of a robotic platform cannot predict an individual patient’s outcome.

Clinical question

Population: adults after primary TKA. Intervention: robotic-assisted TKA. Comparator: conventional TKA. Outcomes: pain and function measured with PROMs, complications, reoperations, revisions, and implant survivorship at a stated time point.

The search for this version was updated on 8 August 2026.

Available evidence

A meta-analysis of 21 randomized trials involving 2,692 participants found no significant differences in WOMAC or Oxford Knee Scores at the reported time points, although radiographic outliers were less common with robotic-assisted TKA [1]. Mean operating time was longer in the robotic group, and studies covered different platforms and protocols.

A separate systematic review and meta-analysis compared survivorship after robotic and conventional TKA [2]. These estimates are highly time-dependent: uncommon events and relatively young technologies require large registries and long observation. Early survivorship cannot establish a long-term advantage.

A propensity-matched CORI cohort compared 215 robotic with 215 conventional TKAs across perioperative measures, 30/90-day complications, PROMs, and revision endpoints [3]. Its retrospective design, two-surgeon setting, and early endpoints limit causal inference and generalizability.

A series of 500 completed CUVIS TKAs describes intraoperative technical events and complications [4]. It helps identify event types but cannot estimate a comparative rate: there was no control group, and cases in which robotic completion was abandoned were excluded.

Findings by endpoint

PROMs and function

Pooled randomized evidence does not show a consistent WOMAC or Oxford Knee Score advantage. Some studies report early differences, but instruments, assessment times, and minimal clinically important differences vary.

Complications

Small series are poorly suited to uncommon events. General surgical complications, potentially system-related events, and technical interruptions without patient harm should be reported separately. No event in a small sample does not mean zero risk.

Revision and survivorship

Survivorship requires both a revision definition and a time horizon. Current platforms may not have existed long enough to assess late revision mechanisms reliably. Better alignment or component position must not be converted automatically into a lower revision claim.

Limitations

Different platforms, versions, implants, and alignment strategies are grouped as “robotic.”
PROMs are influenced by baseline status, rehabilitation, and many factors beyond the platform.
Retrospective studies are vulnerable to patient selection and surgeon-experience differences.
Uncommon complications and revisions need much larger samples than accuracy endpoints.
Conflicts of interest and publication bias should be checked in every paper.

Interpretation

Current evidence does not justify presenting technical reproducibility as guaranteed improvement in symptoms or implant longevity. Claims of benefit require a clinically meaningful effect size, confidence interval, follow-up, and applicability to the actual platform.

References

This review reflects the evidence available as of the stated search date. Studies may differ in systems, versions, populations, methods, and follow-up. Research findings cannot predict an individual outcome and do not replace a discussion of treatment options with a healthcare professional.